Abstract
Painless Thyroiditis Induced by Immune Checkpoint Inhibitors in a Patient with Small Cell Lung Cancer
Highlights
New antineoplastic agents consisting of specific monoclonal antibodies which enhance the host’s immune response against the tumoral cells are becoming more common in clinical practice
Ipilimumab, an antibody that blocks the cytotoxic T-lymphocyte antigen 4 (CTLA-4), and nivolumab, a programmed cell death 1 (PD-1) inhibitor are approved for several advanced neoplasias such as melanoma, non-small cell lung cancer and renal cell carcinoma [1]
In this paper we present a case of checkpoint inhibitor-induced thyroiditis in a patient with metastatic small cell lung cancer (SCLC)
Summary
New antineoplastic agents consisting of specific monoclonal antibodies which enhance the host’s immune response against the tumoral cells are becoming more common in clinical practice. Painless Thyroiditis Induced by Immune Checkpoint Inhibitors in a Patient with Small Cell Lung Cancer *Corresponding author: Maria Jose Burches Feliciano, Servicio de Endocrinología y Nutrición, Hospital Universitari i Politècnic La Fe Valencia, Spain
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
